

**THE CLAIMS**

Please amend claims 4 and 7 to read as follows:

1           1. (Previously Presented) A method for controlling chronic inflammation associated with  
2 Metabolic Syndrome in an individual having the Metabolic Syndrome, comprising:  
3           administering to said individual an effective dosage of a pharmaceutical composition  
4 selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate  
5 Subfraction, and a combination thereof.

1           2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by  
2 at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

1           3. (Previously Presented) The method of claim 1, wherein the chronic inflammation is  
2 evidenced by at least one of elevated platelet count and elevated platelet activity.

1           4. (Currently Amended) The method of claim 1, wherein the individual has at least one  
2 condition selected from the group consisting of hypertension, hypercholesterolemia,  
3 hypertriglyceridemia, and obesity as part of the Metabolic syndrome.

1           5. (Canceled)

1           6. (Previously Presented) The method of claim 1, wherein the individual has at least one  
2 condition selected from the group consisting of obesity, insulin resistance, hypertension,  
3 dyslipidemia, impaired glucose tolerance, accompanied by increased acute phase proteins  
4 including C-Reactive Protein and fibrinogen.

1           7. (Currently Amended) The method of claim 1, wherein said individual has diabetes  
2 mellitus, coronary artery disease or cancer as part of the Metabolic syndrome.

1           8. (Original) A method for controlling elevated blood glucose level in an individual with  
2 inflammation-related metabolic disturbances, comprising:

3 administering to said individual an effective dosage of a composition selected from the  
4 group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a  
5 combination thereof.

1 9. (Original) The method of claim 8, wherein the individual has at least one component  
2 of the Metabolic Syndrome.

1 10. (Original) A method for preventing chronic inflammation due to the presence of or  
2 potential exposure to a pathogen, environmental particulates, or environmental toxins, said  
3 method comprising: administering to said individual an effective dosage of a pharmaceutical  
4 composition selected from the group consisting of YG-Product, YGG-Product, Purified  
5 Leukocyte Dialysate Subfraction, and a combination thereof.

1 11. (Original) A method for mitigating a symptom in a patient, said symptom  
2 characteristic of chronic inflammation, said patient presenting said symptom, said method  
3 comprising administering to the patient a pharmaceutical preparation containing an effective  
4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a  
5 combination thereof.

1 12. (Original) The method of claim 11, wherein said patient has at least one component  
2 of the Metabolic Syndrome.

1 13. (Previously Presented) The method of claim 12, wherein said symptom is at least one  
2 selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,  
3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory  
4 state, and a prothrombotic state.

1 14. (Original) A method for mitigating a symptom in a patient, said symptom  
2 characteristic of an inflammation-related metabolic disturbance, said patient presenting said  
3 symptom, said method comprising administering to the patient a pharmaceutical preparation

4 containing an effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte  
5 Dialysate Subfraction, or a combination thereof.

1 15. (Original) The method of claim 14, wherein said patient has at least one component  
2 of the Metabolic Syndrome.

1 16. (Previously Presented) The method of claim 15, wherein said component is at least  
2 one selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,  
3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory  
4 state, and a prothrombotic state.

1 17. (Original) A method for deferring the progression of a patient from the Metabolic  
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer,  
3 said method comprising administering to the patient a pharmaceutical preparation containing an  
4 effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate  
5 Subfraction, or a combination thereof.

1 18. (Previously Presented) A method for preventing or mitigating development of  
2 inflammation-related sequelae of exposure of a person to liquids or vapors containing organic  
3 solvents or hydrocarbon fuels, or to environmental toxins capable of provoking chronic  
4 inflammation, said method comprising:

5 (a) administering to the person a pharmaceutical preparation containing an effective  
6 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a  
7 combination thereof;

8 (b) monitoring the person for immune function response, inflammation, and blood  
9 glucose level; and

10 (c) continuing to administer to the patient said pharmaceutical preparation until the  
11 person shows a normal immune function response and normal measures of inflammatory  
12 parameters.